MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:37Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:ACE inhibitors]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #211

2026-05-23T04:00:15Z

parser-claude batch MedTemplate pre-fill, Top 300 #211

New page

{{MedTemplate
| generic = Ramipril
| brand = Altace
| structure =
| classes = [[:Category:ACE_inhibitors|ACE inhibitor]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="hypertension-use">Hypertension</vote>, <vote slug="heart-failure-use">Heart failure</vote>, <vote slug="post-mi-use">Post-myocardial infarction (LV dysfunction)</vote>, <vote slug="cv-risk-reduction-acei-use">Cardiovascular risk reduction in high-risk patients (per HOPE)</vote>
| starting_dose = 2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d
| preparations = 1.25, 2.5, 5, 10 mg capsules
| fda_max = 20 mg/d (hypertension); 10 mg/d (other indications typical)
| pill_id =
| routes = Oral
| onset = BP effect 1-2 hours; max at 6 hours
| duration = 24 hours
| halflife = ~13-17 hours (ramiprilat, the active metabolite)<ref name="altace-label">FDA Prescribing Information, Altace (ramipril), Pfizer/King, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019901s063lbl.pdf</ref>
| bioavailability = ~28% (oral; food slows but does not reduce absorption)<ref name="altace-label" />
| pregnancy = '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension<ref name="altace-label" />
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="ramipril-mech-claim">Ramipril is a prodrug hydrolyzed to ramiprilat, a long-acting ACE inhibitor that blocks conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and renal sodium retention.</vote> The HOPE trial (2000) demonstrated cardiovascular risk reduction in high-risk patients with vascular disease or diabetes, independent of BP lowering — establishing the broader "ACE inhibitors for vascular protection" indication beyond hypertension and heart failure<ref name="altace-label" />.
}}

== References ==
<references />

Ramipril - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #211